N/A N=45 Clinical Comparison of Two Marketed Reusable Cosmetic Contact Lenses
Visual Acuity
Primary: Visual Performance — 0.40; 0.38; -0.09; -0.10 logMAR Units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=45 Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 4; 4; 4; 4 Participants
Phase 1 N=90 The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants
Migraine
Primary: Simulated Driving Performance in Healthy Participants as Measured by Standard Deviation of Lateral Position (SDLP) Using the Cognitive Research Corporation Driving…
N/A N=555 Randomized Controlled Trial of Wellness Recovery Action Planning
Mental Disorders
Primary: Psychiatric Symptoms Recovery Using the Brief Symptoms Inventory (BSI) — 20.6; 19.29; 19.52; 21.38 symptom severity score — p=0.027
Phase 2 N=66 Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities — 0; 0 Participants
N/A N=436 Promoting Veteran-Centered Colorectal Cancer Screening
Colorectal Cancer
Primary: Number of Participants With CRC Screening Ordered — 162; 114 Participants — p=0.491
Phase 1 N=70 A Study of Multiple Doses of Lasmiditan in Healthy Participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 1 N=18 A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers
Healthy Volunteers
Primary: Period 1: Maximum Plasma Concentration (Cmax) of Pitavastatin — 23.8 ng/mL
Phase 3 N=356 The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
Constipation Predominant Irritable Bowel Syndrome
Primary: Percent Complete Spontaneous Bowel Movement Responders vs Placebo — 35; 38; 51; 30 Participants — p=<0.001
N/A N=73 VELOCITY: A Study to Characterize Real-World Outcomes of Spinal Cord Stimulation
Chronic Pain
Primary: Percentage of Low Back Pain Responders — 25; 23 Participants
N/A N=346 Evaluation and Treatment of Substance Abuse in Veterans With PTSD Disability Claims
Attendance at Treatment · PTSD, Substance Use, and Attendance at Treatment
Primary: Treatment Attendance by Treatment Group Over Time — 0.75; 0.53; 0.83; 0.89 weeks
Phase 2 N=10 Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Locally Advanced Malignant Neoplasm · Breast Cancer
Primary: Mean Adherence to Propranolol — 96 Percentage of propanolol adherence
Phase 3 N=120 Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
Pigmented Villonodular Synovitis · Giant Cell Tumors of the Tendon Sheath · Tenosynovial Giant Cell Tumor
Primary: Percentage of Participants With Symptomatic, Locally Advanced Tenosynovial Giant Cell Tumor (TGCT) Achieving Complete or Partial Response to Pexidartinib Compared With…
Phase 1 N=32 Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)
Renal Insufficiency
Primary: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) Post-dose Period 1 — 110; 260; 364; 176 pg*hr/mL
Phase 4 N=102 Study of Exparel Versus Epidural for Pain Control After Thoracotomy
Pain Following Thoracotomy Surgery
Primary: Pain Scores With Cough on First Postoperative Day — 6.1; 6.9 units on a scale — p=0.142